Clinical Study On Transurethral Surounding Blader Tumor En Bloc Resectioncombined With Intravesical Chemotherapy At Super Early Stage

Background and purposeTo evaluate the safety and clinical efficacy of TURSEBT combined with intravesical chemotherapy at super early stage and c TURBT combined with early gemcitabine infusion chemotherapy in patients with NMIBC.MethodsA total of 79 NMIBC patients undergoing TURBT admitted from the First Department of Urology of Harbin Medical University Cancer Hospital during September 2014 to September 2019,who was confirmed by pathological examination,were divided into modified surgery group(TURSEBT group=34)and traditional surgery group(c TURBT group,n=45).In the modified operation group,the tumor was enucleated by TURSEBT and the resection mirror was taken out after the operation and the bladder flushing fluid was drained.1.0g gemcitabine was immediately perfused,that is,ultra-early infusion chemotherapy.The control group was treated with traditional resection combined with Gemcitabine in 24 hours after the operation.The operation time,Postoperative hospital stay,postoperative hemoglobin reduction,postoperative catheter indwelling time,postoperative complications,postoperative recurrence,and other clinical data were compared between the two groups.ResultsThe survival rate of the two groups was 100%,and the incidence of bladder perforation was 0%.Comparing the operation conditions of the two groups,there was no significant difference in the operation time and the incidence of obturator nerve reflex between the two groups(P> 0.05),but the Postoperative hospital stay was significantly reduced(P <0.05);Comparing the postoperative recovery of the two groups of patients,there was no significant difference in blood loss and postoperative complications(P> 0.05),but the postoperative catheter indwelling time improved surgery group was significantly shorter(P <0.05).The postoperative follow-up was 12-60 months.There was no statistically significant comparison of the recurrence rate between the two groups in 6 months,1 year,and 2 years after the operation.The recurrence rate of the modified surgery group was significantly lower than that of the control group in 3 years,and the difference was significant(P < 0.05).ConclusionsThe use of TURSEBT combined with intravesical chemotherapy at super early stage can reduce the long-term recurrence rate,and can shorten the postoperative catheter indwelling time and Postoperative hospital stay,which has clinical application value.